ArticleRevista Brasileira de terapia intensiva

Rationale and design of the "Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS).

Danielle Leão Cordeiro de Farias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.